Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

R. Spigel, David; Faivre-Finn, Corinne; E. Gray, Jhanelle; Vicente, David; Planchard, David; Paz-Ares, Luis; F. Vansteenkiste, Johan; C. Garassino, Marina; Hui, Rina; Quantin, Xavier; Rimner, Andreas; Wu, Yi-Long; Özgüroğlu, Mustafa; H. Lee, Ki; Kato, Terufumi; de Wit, Maike; Kurata, Takayasu; Reck, Martin; C. Cho, Byoung; Senan, Suresh; Naidoo, Jarushka; Mann, Helen; Newton, Michael; Thiyagarajah, Piruntha; J. Antonia, Scott

doi:10.1200/jco.21.01308

Public

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Feb 2, 2022

Authors:

David R. Spigel

Corinne Faivre-Finn

Jhanelle E. Gray

Abstract

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of o...

Subject

Durvalumab

Medicine

Chemoradiotherapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!